Quantitative Analysis of Somatostatin and Dopamine Receptors Gene Expression Levels in Non-functioning Pituitary Tumors and Association with Clinical and Molecular Aggressiveness Features

The primary treatment for non-functioning pituitary tumors (NFPTs) is surgery, but it is often unsuccessful. Previous studies have reported that NFPTs express receptors for somatostatin (SST1-5) and dopamine (DRDs) providing a rationale for the use of dopamine agonists and somatostatin analogues. He...

Descripción completa

Detalles Bibliográficos
Autores: Flores-Martínez, Alvaro, Venegas Moreno, Eva, Dios Fuentes, Elena, Remón-Ruiz, Pablo, Gros Herguido, Noelia, Vázquez-Borrego, Mari C., Madrazo Atutxa, Ainara, Japón, Miguel A., Kaen, Ariel, Cárdenas Ruiz-Valdepeñas, Eugenio, Roldán, Florinda, Castaño, Justo P., Luque, Raúl M., Cano González, David A., Soto-Moreno, Alfonso
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2020
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/415544
Acceso en línea:http://hdl.handle.net/10261/415544
https://api.elsevier.com/content/abstract/scopus_id/85114273483
Access Level:acceso abierto
Palabra clave:Somatostatin receptor
Dopamine receptor
Invasion
Non-functioning pituitary tumors
Pituitary tumor
Descripción
Sumario:The primary treatment for non-functioning pituitary tumors (NFPTs) is surgery, but it is often unsuccessful. Previous studies have reported that NFPTs express receptors for somatostatin (SST1-5) and dopamine (DRDs) providing a rationale for the use of dopamine agonists and somatostatin analogues. Here, we systematically assessed SST1-5 and DRDs expression by real-time quantitative PCR (RT-qPCR) in a large group of patients with NFPTs (n = 113) and analyzed their potential association with clinical and molecular aggressiveness features. SST1-5 expression was also evaluated by immunohistochemistry. SST3 was the predominant SST subtype detected, followed by SST2, SST5, and SST1. DRD2 was the dominant DRD subtype, followed by DRD4, DRD5, and DRD1. A substantial proportion of NFPTs displayed marked expression of SST2 and SST5. No major association between SSTs and DRDs expression and clinical and molecular aggressiveness features was observed in NFPTs.

Similares en LA Referencia